Hong Kong, 2 June 2026 – HighTide Therapeutics, Inc. has issued a notice convening its Annual General Meeting (AGM) for 10:00 a.m. on Monday, 29 June 2026, at Meeting Room 24, 2/F, Building 10W, Hong Kong Science Park, New Territories.
Key items on the agenda:
1. Financial Statements • Shareholders will vote to receive and adopt the audited consolidated financial statements for the year ended 31 December 2025 together with the directors’ and auditor’s reports.
2. Board Composition • Re-election of four retiring directors: – Dr Liu Liping (Executive Director) – Mr Ma Lixiong (Non-executive Director) – Mr Hung Tak Wai (Independent Non-executive Director) – Mr Chen Mingyu (Independent Non-executive Director) • The Board will be authorised to set directors’ remuneration.
3. Auditor • Moore CPA Limited is nominated for re-appointment, with remuneration to be fixed by the Board.
4. Capital Mandates • General issue mandate: authority to allot and issue new shares—or dispose of treasury shares—up to 20% of the company’s issued share capital (excluding treasury shares) as at the date of the AGM. • Share buy-back mandate: authority to repurchase up to 10% of issued shares (excluding treasury shares) on the Stock Exchange or other recognised markets. • Extension mandate: the issue mandate may be increased by the number of shares repurchased under the buy-back mandate, capped at an additional 10% of issued shares.
Administrative details:
• Share register closure: 24–29 June 2026 (both days inclusive); only shareholders on record at 29 June 2026 may attend and vote. • Proxy submission deadline: 10:00 a.m., 27 June 2026, at Computershare Hong Kong Investor Services Limited. • Non-registered shareholders holding shares via CCASS should contact their intermediaries to arrange attendance or voting.
As of the notice date, the Board comprises eight directors, led by Executive Director and CEO Dr Liu Liping.